Skip Navigation

European Journal of Heart Failure 2006 8(2):215; doi:10.1016/j.ejheart.2006.01.003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Parissis, J. T.
Right arrow Articles by Kremastinos, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parissis, J. T.
Right arrow Articles by Kremastinos, D. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society of Cardiology

Levosimendan therapy in decompensated chronic heart failure: Favourable haemodynamic and neurohormonal effects but for how long?

John T. Parissis*, Dimitrios Farmakis and Dimitrios T. Kremastinos

Second Dept. of Cardiology, University of Athens Medical School, Attikon University Hospital Athens, Greece

* Corresponding author. Aftokratoros Irakliou 17 Str, Maroussi, Athens 15122, Greece. Tel.: +30 210 612 3720. E-mail address: jparissis@yahoo.com

Received August 21, 2005;
The first 10% of the full text of this article appears below.

Dear Editor,

Levosimendan, a novel positive inotropic agent that acts by enhancing calcium sensitivity of cardiac myofilaments, has been shown to have a favourable effect on central haemodynamics and neurohormonal and inflammatory activation [1,2]. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?